Intratumoral mRNA-2416 monotherapy appears safe for patients with solid tumors

Intratumoral mRNA-2416, a lipid nanoparticle therapeutic agent expressing the wild-type human OX40L, appeared safe among a cohort of patients with locally advanced, recurrent or metastatic solid tumors, according to results of a phase 1/2 first-in-human study presented at the virtual American Association for Cancer Research Annual Meeting.